Market cap
$954 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -25.75 | -16.21 | -14.68 | 0.65 | -211.49 |
| Net Profit | -14.34 | -5.67 | -11.51 | 1.54 | -210.71 |
| EPS | -12.38 | 3.87 | -6.11 | 3.44 | -24.20 |
| Book Value | -- | -- | -13.22 | -14.15 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -6,645.89 | -- | -- | -- |
| Return on equity
| -23.96 | -21.52 | -34.17 | -30.70 | -19.08 |
| Return on Capital
| -23.73 | -21.30 | -- | -30.45 | -18.88 |
| Return on Assets
| -22.90 | -20.27 | -30.91 | -29.18 | -18.31 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
-30.45
|
-18.88
|
-21.86
|
-16.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-34.17
Higher than Peers by 6.23
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-34.17
|
-30.70
|
-19.08
|
-22.10
|
-16.52
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-30.91
Higher than Peers by 0.06
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-30.91
|
-29.18
|
-18.31
|
-21.20
|
-16.02
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
-1,367.96
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-14.68
Lower than Peers by 13.88
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-14.68
|
-40.74
|
25.84
|
1.08
|
-90.23
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-11.51
Lower than Peers by 4.21
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-11.51
|
-40.74
|
25.84
|
-14.07
|
-64.96
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-6.11
Lower than Peers by 20.76
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-6.11
|
-0.39
|
0.27
|
-0.13
|
-0.63
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-13.81
Lower than Peers by 3.63
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-13.81
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
18.86
Higher than Peers by 13.05
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
18.86
|
17.14
|
29.31
|
29.58
|
31.10
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
18.86
Higher than Peers by 13.17
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
18.86
|
--
|
--
|
--
|
31.20
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
-14.41
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
-758.39
|
54.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
1,320.65
|
1,264.28
|
1,688.52
|
1,820.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
-7.71
|
-7.05
|
-2.23
|
-9.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
4.73
Lower than Peers by 0.45
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
4.73
|
2.53
|
1.44
|
0.54
|
1.75
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.84
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
-0.84
|
-4.62
|
-2.18
|
1.96
|
-3.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
954
Higher than Peers by 808
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
954
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|